CirculoGene provides blood-based testing for detecting clinically significant tumor DNA/RNA alterations. The company uses a patented methodology for DNA yield and RNA preservation, employing next-generation sequencing and polymerase chain reaction instrumentation for DNA and RNA detection.

CirculoGene

Headquartered in Birmingham, Ala., CIRCULOGENE is an innovative molecular diagnostics company founded and operated by a team of experienced industry executives and skilled molecular diagnostics scientists. Applying its proprietary laboratory developed test for cfDNA, cfRNA and MSI liquid biopsies, CIRCULOGENE has developed a next-generation sequencing (NGS) method to provide full genomic load analysis from one standard tube of blood in one week, enabling more accurate data to help clinicians and their patients choose targeted therapies, monitor efficacy and monitor for recurrence. One tube, one week, complete results. Somatic + Germline; Blood + Tissue + Buccal; DNA + RNA + MSI + PD-L1. 

CONTACT
info@circulogene.com

For Asia Pacific inquiries,
please email AsiaPacfic@circulogene.com

For Middle Eastern inquiries,
please email Irem.Agin@circulogene.com.tr

CIRCULOGENE

Tumor markers play a crucial role in the diagnosis and management of cancer. At Circulogene, our TumorClear test uses next-generation sequencing to provide a detailed molecular profile of your tumor, including essential guideline and expert-recommended DNA mutations. This comprehensive analysis helps your physician tailor a treatment plan that is specifically designed for your unique cancer. Learn more about the significance of tumor markers and how they can influence your treatment at https://lnkd.in/exce_3h9

At Circulogene, we harness the power of advanced diagnostics technology to revolutionize healthcare. Our proprietary methodologies, including next-generation sequencing (NGS) and polymerase chain reaction (PCR), allow us to provide comprehensive and precise diagnostic results. By utilizing these state-of-the-art techniques, we offer unparalleled accuracy in detecting tumor DNA and RNA, enabling personalized treatment plans for our patients. Discover more about how we are leading the way in medical innovation at https://lnkd.in/exce_3h9

I recently heard from a friend that his parent had been diagnosed with stage 4 cancer. We are very lucky to live at a time when there are exceptional diagnostic tools, procedural tools, doctors/staff, treatment options and facilities available to treat patients with stage 4 cancer, improving outcomes and life expectancy.
Several years ago, when my father was battling his cancer, he would tell me he was going to win and beat this! We cheered him on as he fought the good fight and I knew it made a difference for him that we were all fighting at his side. It wasn’t enough, he lived for a year and 2 weeks after his diagnosis. As you might expect, i think about him often and wonder if he had current opinions available to him, would he still be alive?
There are many warriors out there who have a much better chance at winning today than my father did because there are many more weapons to use. I work in the cancer diagnostic industry and have met many exceptional people who are fighting cancer as physicians, nurses, program directors, and industry leaders. We are all working to provide the best options for each individual. 
I was missing my dad today and hoping my friend and his family can win. Im cheering for them as well.

#findacure
#cancersucks
#warriorlife

Why Circulogene? Complete, Accurate, and Timely Testing.

Dr. Walker is one of the most trusted professionals in the industry. Hear as he walks us thorugh the importance of liquid biposy testing for early detection.

Hear from Mike Mullen our founder, on "Why Circulogene".

Metric
Company Name	CirculoGene
Symbol
MSH ID	COM:CIRCULOGENE
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology and Medical Diagnostics
Country	US
Stage
Employee Count	38
Website	circulogene.com
LinkedIn	circulogene-diagnostics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CIRC

COM:CIRCULOGENE

CirculoGene

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue